Cross-Resistance to Camptothecin Analogues in a Mitoxantrone-resistant Human Breast Carcinoma Cell Line Is Not Due to DNA Topoisomerase I Alterations

Chih Hsin J. Yang, Kenneth H Cowan, Julie K. Horton, Erasmus Schneider

Research output: Contribution to journalArticle

95 Citations (Scopus)

Abstract

We have previously described a mitoxantrone-resistant human breast carcinoma cell line, MCF7/MX, in which resistance was associated with a defect in the energy-dependent accumulation of mitoxantrone in the absence of P-glycoprotein overexpression (M. Nakagawa et aL, Cancer Res. 52: 6175–6181, 1992). We now report that this cell line is highly cross-resistant to the camptothecin analogues topotecan (180-fold), 9-aminocamptothecin (120-fold), CPT-11 (56-fold), and SN38 (101-fold), but is only mildly cross-resistant to the parent compound camptothecin (3.2-fold) and 10,11-methylenedioxy-camptothecin (2.9-fold). Topotecan accumulation was decreased in MCF7/MX cells compared to parental MCF7/WT cells, and there was a corresponding reduction in topotecan-mediated stimulation of the enzyme/DNA complex formation in MCF7/MX cells compared to MCF7/WT cells. No overexpression of the multidrug resistance-associated protein was detected compared to parental MCF7/WT cells. Furthermore, both sensitive MCF7/WT and mitoxantrone-resistant MCF7/MX cells contain equal amounts of DNA topoisomerase I protein, and DNA relaxation activities were equal in both cell lines and inhibited to the same extent by topotecan and camptothecin. Thus, these results suggest a novel mechanism of resistance to topoisomerase I inhibitors in cancer cells.

Original languageEnglish (US)
Pages (from-to)4004-4009
Number of pages6
JournalCancer Research
Volume55
Issue number18
StatePublished - Sep 15 1995

Fingerprint

Camptothecin
Mitoxantrone
Type I DNA Topoisomerase
MCF-7 Cells
Topotecan
irinotecan
Breast Neoplasms
Cell Line
9-aminocamptothecin
Topoisomerase I Inhibitors
Multidrug Resistance-Associated Proteins
DNA
P-Glycoprotein
Neoplasms
Enzymes
Proteins

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Cross-Resistance to Camptothecin Analogues in a Mitoxantrone-resistant Human Breast Carcinoma Cell Line Is Not Due to DNA Topoisomerase I Alterations. / Yang, Chih Hsin J.; Cowan, Kenneth H; Horton, Julie K.; Schneider, Erasmus.

In: Cancer Research, Vol. 55, No. 18, 15.09.1995, p. 4004-4009.

Research output: Contribution to journalArticle

@article{977a691846684addbb7bd3b1b1c09a86,
title = "Cross-Resistance to Camptothecin Analogues in a Mitoxantrone-resistant Human Breast Carcinoma Cell Line Is Not Due to DNA Topoisomerase I Alterations",
abstract = "We have previously described a mitoxantrone-resistant human breast carcinoma cell line, MCF7/MX, in which resistance was associated with a defect in the energy-dependent accumulation of mitoxantrone in the absence of P-glycoprotein overexpression (M. Nakagawa et aL, Cancer Res. 52: 6175–6181, 1992). We now report that this cell line is highly cross-resistant to the camptothecin analogues topotecan (180-fold), 9-aminocamptothecin (120-fold), CPT-11 (56-fold), and SN38 (101-fold), but is only mildly cross-resistant to the parent compound camptothecin (3.2-fold) and 10,11-methylenedioxy-camptothecin (2.9-fold). Topotecan accumulation was decreased in MCF7/MX cells compared to parental MCF7/WT cells, and there was a corresponding reduction in topotecan-mediated stimulation of the enzyme/DNA complex formation in MCF7/MX cells compared to MCF7/WT cells. No overexpression of the multidrug resistance-associated protein was detected compared to parental MCF7/WT cells. Furthermore, both sensitive MCF7/WT and mitoxantrone-resistant MCF7/MX cells contain equal amounts of DNA topoisomerase I protein, and DNA relaxation activities were equal in both cell lines and inhibited to the same extent by topotecan and camptothecin. Thus, these results suggest a novel mechanism of resistance to topoisomerase I inhibitors in cancer cells.",
author = "Yang, {Chih Hsin J.} and Cowan, {Kenneth H} and Horton, {Julie K.} and Erasmus Schneider",
year = "1995",
month = "9",
day = "15",
language = "English (US)",
volume = "55",
pages = "4004--4009",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "18",

}

TY - JOUR

T1 - Cross-Resistance to Camptothecin Analogues in a Mitoxantrone-resistant Human Breast Carcinoma Cell Line Is Not Due to DNA Topoisomerase I Alterations

AU - Yang, Chih Hsin J.

AU - Cowan, Kenneth H

AU - Horton, Julie K.

AU - Schneider, Erasmus

PY - 1995/9/15

Y1 - 1995/9/15

N2 - We have previously described a mitoxantrone-resistant human breast carcinoma cell line, MCF7/MX, in which resistance was associated with a defect in the energy-dependent accumulation of mitoxantrone in the absence of P-glycoprotein overexpression (M. Nakagawa et aL, Cancer Res. 52: 6175–6181, 1992). We now report that this cell line is highly cross-resistant to the camptothecin analogues topotecan (180-fold), 9-aminocamptothecin (120-fold), CPT-11 (56-fold), and SN38 (101-fold), but is only mildly cross-resistant to the parent compound camptothecin (3.2-fold) and 10,11-methylenedioxy-camptothecin (2.9-fold). Topotecan accumulation was decreased in MCF7/MX cells compared to parental MCF7/WT cells, and there was a corresponding reduction in topotecan-mediated stimulation of the enzyme/DNA complex formation in MCF7/MX cells compared to MCF7/WT cells. No overexpression of the multidrug resistance-associated protein was detected compared to parental MCF7/WT cells. Furthermore, both sensitive MCF7/WT and mitoxantrone-resistant MCF7/MX cells contain equal amounts of DNA topoisomerase I protein, and DNA relaxation activities were equal in both cell lines and inhibited to the same extent by topotecan and camptothecin. Thus, these results suggest a novel mechanism of resistance to topoisomerase I inhibitors in cancer cells.

AB - We have previously described a mitoxantrone-resistant human breast carcinoma cell line, MCF7/MX, in which resistance was associated with a defect in the energy-dependent accumulation of mitoxantrone in the absence of P-glycoprotein overexpression (M. Nakagawa et aL, Cancer Res. 52: 6175–6181, 1992). We now report that this cell line is highly cross-resistant to the camptothecin analogues topotecan (180-fold), 9-aminocamptothecin (120-fold), CPT-11 (56-fold), and SN38 (101-fold), but is only mildly cross-resistant to the parent compound camptothecin (3.2-fold) and 10,11-methylenedioxy-camptothecin (2.9-fold). Topotecan accumulation was decreased in MCF7/MX cells compared to parental MCF7/WT cells, and there was a corresponding reduction in topotecan-mediated stimulation of the enzyme/DNA complex formation in MCF7/MX cells compared to MCF7/WT cells. No overexpression of the multidrug resistance-associated protein was detected compared to parental MCF7/WT cells. Furthermore, both sensitive MCF7/WT and mitoxantrone-resistant MCF7/MX cells contain equal amounts of DNA topoisomerase I protein, and DNA relaxation activities were equal in both cell lines and inhibited to the same extent by topotecan and camptothecin. Thus, these results suggest a novel mechanism of resistance to topoisomerase I inhibitors in cancer cells.

UR - http://www.scopus.com/inward/record.url?scp=0029091756&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029091756&partnerID=8YFLogxK

M3 - Article

VL - 55

SP - 4004

EP - 4009

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 18

ER -